Kiniksa Q3 ARCALYST revenue $64.8M (+94% YoY); tracking to high end of FY guidance

Kiniksa Pharmaceuticals International, plc

2023-Q3 EPS reported -$0.16 revenue$186,864,000

ARCALYST net product revenue $64.8M, ~94% YoY growth; total revenue $67.0M (incl. $2.2M license).
Net loss $13.9M vs net income $224.1M in Q3 2022 (prior year included $65.7M license revenue).
Cash $201.1M, no debt; expected to fund operations into at least 2027.
KPL-404 Phase 2 RA data from Cohorts 1-3 expected Q1 2024; Cohort 4 data expected Q2 2024.
FY2023 ARCALYST revenue guidance $220-230M, tracking to high end.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.4

Kiniksa Pharmaceuticals International, plc reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

On October 31, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-23-112750

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.